Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
Lifecore Biomedical, Inc. De (LFCR)
Price$4.46Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
Financial statements
| 2025 · Dec 31 | 2025 · May 25 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.5M | $128.9M | $128.3M | $103.3M | $111.3M | $100.9M | $160.1M | $557.6M | $524.2M | $469.8M | $476.9M | $539.3M | $476.8M | $441.7M | $317.6M | $276.7M | $238.2M |
| Gross profit | $23.7M | $40.3M | $41.9M | $28.0M | $39.1M | $38.9M | $39.4M | $81.0M | $78.3M | $79.2M | $66.8M | $65.4M | $62.6M | $62.8M | $52.1M | $46.7M | $33.8M |
| Gross margin | 31.37% | 31.27% | 32.63% | 27.10% | 35.11% | 38.60% | 24.61% | 14.53% | 14.94% | 16.86% | 14.00% | 12.13% | 13.12% | 14.21% | 16.42% | 16.87% | 14.17% |
| Research & development | $5.0M | $8.3M | $8.6M | $8.7M | $7.8M | $6.7M | $7.6M | $11.5M | $12.8M | $9.5M | $7.2M | $7.0M | $7.2M | $9.3M | $9.6M | $9.3M | $4.4M |
| Operating expenses | $24.4M | $57.5M | $50.7M | $49.8M | $50.9M | $47.8M | $65.3M | $75.5M | $64.8M | $64.5M | $87.4M | $46.9M | $42.4M | $37.9M | $37.6M | $38.7M | $25.8M |
| Operating income | −$733,000 | −$17.2M | −$8.8M | −$21.8M | −$11.8M | −$8.8M | −$25.9M | $5.5M | $13.6M | $14.7M | −$20.6M | $18.5M | $20.2M | $24.9M | $14.6M | $8.0M | $8.0M |
| Operating margin | −0.97% | −13.38% | −6.90% | −21.11% | −10.60% | −8.75% | −16.17% | 0.98% | 2.59% | 3.12% | −4.33% | 3.42% | 4.23% | 5.63% | 4.59% | 2.90% | 3.35% |
| EBITDA | $4.9M | −$9.2M | −$890,000 | −$8.6M | $6.3M | $11.0M | −$7.0M | $20.7M | $26.0M | $25.3M | −$11.2M | $25.6M | $27.3M | $32.2M | $20.2M | $13.3M | $11.3M |
| EBITDA margin | 6.49% | −7.15% | −0.69% | −8.35% | 5.63% | 10.95% | −4.40% | 3.71% | 4.96% | 5.40% | −2.36% | 4.74% | 5.73% | 7.28% | 6.36% | 4.82% | 4.76% |
| Net income | −$18.0M | −$38.7M | $12.0M | −$99.6M | −$116.7M | −$32.3M | −$38.2M | $411,000 | $24.8M | $10.6M | −$11.6M | $13.5M | $19.1M | $22.6M | $12.7M | $3.9M | $4.0M |
| Net profit margin | −23.78% | −30.04% | 9.37% | −96.41% | −104.89% | −32.01% | −23.86% | 0.07% | 4.74% | 2.25% | −2.44% | 2.51% | 4.02% | 5.11% | 4.00% | 1.42% | 1.67% |
| Basic EPSper basic share | -$0.54 | -$1.27 | $0.39 | -$3.32 | -$3.97 | -$1.10 | -$1.31 | $0.01 | $0.90 | $0.39 | -$0.43 | $0.50 | $0.72 | $0.87 | $0.49 | $0.15 | $0.15 |
| Diluted EPSper diluted share | -$0.54 | -$1.27 | $0.33 | -$3.32 | -$3.97 | -$1.10 | -$1.31 | $0.01 | $0.89 | $0.38 | -$0.43 | $0.50 | $0.71 | $0.85 | $0.49 | $0.15 | $0.15 |
Owners
Reported shareholders
12.48%of listed shares
WYNNEFIELD CAPITAL INC4.7M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
WYNNEFIELD CAPITAL INC | 12.48%4.7M shares |
Legion Partners Asset Management, LLC | 11.84%4.46M shares |
Greenhaven Road Investment Management, L.P. | 8.46%3.19M shares |
325 CAPITAL LLC | 7.68%2.9M shares |
BlackRock, Inc. | 5.34%2.01M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.42%1.29M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.27%855.5K shares |
MORGAN STANLEY | 2.04%769.36K shares |
STATE STREET CORP | 1.77%668.03K shares |
Josephs Paul | ≈1.57%592.92K shares |
Quinn Opportunity Partners LLC | 1.20%453.5K shares |
DCF Advisers, LLC | 1.13%424.5K shares |
Lake Ryan David | ≈0.89%336.69K shares |
WITTENBERG INVESTMENT MANAGEMENT, INC. | 0.83%314.02K shares |
English Aron R. / 22NW Fund, LP / 22NW, LP / 22NW Fund GP, LLC / 22NW GP, Inc. | ≈0.70%264.18K shares |
NORTHERN TRUST CORP | 0.67%253.82K shares |
Salus Thomas D. | ≈0.65%246.33K shares |
VANGUARD FIDUCIARY TRUST CO | 0.64%239.92K shares |
LPL Financial LLC | 0.55%207.3K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.50%189.07K shares |
Percentages use 37.7M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 28, 2025Form 4 | English Aron R. +4TenPercentOwner | SellCommon Stock · indirect | 150.4K | $7.12 | $1.07M | 264.2K |
| May 27, 2025Form 4 | English Aron R. +4TenPercentOwner | SellCommon Stock · indirect | 1.14M | $6.50 | $7.41M | 414.6K |
| May 23, 2025Form 4 | English Aron R. +4TenPercentOwner | SellCommon Stock · indirect | 96.1K | $6.75 | $648.9K | 1.55M |
| May 13, 2025Form 4 | 22NW Fund GP, LLC +4TenPercentOwner | SellCommon Stock · indirect | 12.3K | $7.00 | $86.3K | 1.65M |
| May 12, 2025Form 4 | 22NW Fund GP, LLC +4TenPercentOwner | SellCommon Stock · indirect | 45.7K | $7.03 | $321.3K | 1.66M |
Community posts
Webster agrees Lifecore buyout with cash and contingent payments
Lifecore Biomedical ($LFCR) has agreed to be acquired by a Webster Equity Partners affiliate. Common shareholders would receive $6.28 in cash per share at closing, a 49.5% premium to the preceding trading day’s close, plus a non-tradable co ...
